Titan Pharmaceuticals Stock

TTNP

US8883147055

Market Closed - Nasdaq 00:00:00 31/10/2026 +04			5-day change	1st Jan Change
0.3220 ^USD	-8.05%		-12.14%	-93.02%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.49M 5.05M 4.58M 8.56M 582M 8.72M 60.24M 24.18M 306M 23.01M 22.52M 966M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.96M 2.72M 2.46M 4.61M 313M 4.69M 32.43M 13.02M 165M 12.39M 12.13M 520M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news: Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
15/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
15/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
02/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
21/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	Titan Pharmaceuticals : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
28/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change
30/10/26	$0.3220	-8.05%
29/10/26	$0.3502	+4.23%
28/10/26	$0.3360	-3.39%
27/10/26	$0.3478	-4.45%
26/10/26	$0.3640	-0.68%

Delayed Quote Nasdaq

More quotes

3 years	0		14.8
5 years	0		35.6
10 years	0		17,280.02

	2023	2024
Net sales	184K 165K 152K 137K 257K 17.47M 262K 1.81M 726K 9.19M 691K 676K 28.98M	-
Net income	-5.57M -4.99M -4.59M -4.16M -7.77M -529M -7.92M -54.71M -21.96M -278M -20.9M -20.46M -877M	-4.71M -4.21M -3.88M -3.51M -6.57M -447M -6.69M -46.23M -18.56M -235M -17.66M -17.29M -741M
Net Debt	-6.2M -5.55M -5.1M -4.62M -8.64M -588M -8.81M -60.86M -24.43M -309M -23.25M -22.75M -976M	-2.83M -2.54M -2.33M -2.11M -3.95M -269M -4.02M -27.81M -11.16M -141M -10.62M -10.4M -446M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news: Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	-8.05%
Current month	-93.02%
Current year	-93.02%